Related Experiment Videos
An overview of the treatment of childhood SLE
Insights
Current pediatric lupus nephritis treatment relies on limited data. Recommendations include azathioprine for diffuse proliferative glomerulonephritis and routine hydroxychloroquine, reserving cyclophosphamide for severe cases.
Area of Science:
- Pediatric Rheumatology
- Immunology
- Nephrology
Background:
- Current pediatric Systemic Lupus Erythematosus (SLE) treatment guidelines lack robust evidence, often relying on adult data or case reports.
- Glucocorticoids are the primary therapy, with dosage adjusted based on disease severity.
- Diffuse proliferative glomerulonephritis (DPGN) necessitates high-dose, long-term prednisone.
Discussion:
- Suggests adding azathioprine for DPGN at diagnosis, reserving cyclophosphamide for refractory cases.
- Contrasts this with aggressive cyclophosphamide/prednisone use advocated by others for lupus nephritis.
- Recommends high-dose prednisone and immunosuppressants for severe central nervous system disease, steroid failure, or dependency.
Key Insights:
- Routine hydroxychloroquine use (5 mg/kg/day, max 400 mg) is advised for all SLE patients.
- Methotrexate shows promise with a good safety profile in pediatric and adult SLE, warranting further investigation.
- Azathioprine is recommended for DPGN, with cyclophosphamide reserved for refractory disease.
Outlook:
- Highlights the need for collaborative development of standardized treatment protocols.
- Emphasizes the necessity of large-scale, multicenter, and multinational data collection to improve outcomes.
- Further research into methotrexate's efficacy and safety in pediatric SLE is crucial.
Abstract:
Current recommendations for the treatment of pediatric SLE are from uncontrolled trials, case reports, retrospective descriptive data or extrapolation from studies in adults. Glucocorticoids are the mainstay of therapy and the doses depend on the disease severity. Diffuse proliferative glomerulonephritis (DPGN) requires high-dose prednisone for prolonged periods of time. We suggest the addition of azathioprine for DPGN at the time of diagnosis of DPGN and reserve cyclophosphamide for refractory cases. While we do not recommend the routine use of cyclophosphamide in this or other forms of lupus nephritis, others advocate the aggressive use of intravenous cyclophosphamide and prednisone. Severe central nervous system disease should be treated with high dose prednisone and immunosuppressive agents are reserved for life-threatening disease or steroid failure or dependency. We suggest the routine use of hydroxychloroquine in all cases of SLE at a dose of 5 mg/kg/day (maximum of 400 mg/day). Methotrexate has been recently used with some success in both children and adults, the safety profile appears to be very good and therefore further studies of this drug are warranted. Collaboration in the development of a limited number of defined treatment protocols and large scale collection of data on a multicenter and multinational basis is needed if we hope to improve the outcome of patients with severe disease.